# C_2013060EN.01000801.xml

| 1.3.2013 | EN | Official Journal of the European Union | C 60/8 |
| --- | --- | --- | --- |

1.3.2013

EN

Official Journal of the European Union

C 60/8

---

COMMISSION DECISION

COMMISSION DECISION

of 28 February 2013

appointing members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals and patient organisations

(Text with EEA relevance)

2013/C 60/03

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (1), and in particular Article 61a(1) thereof,

1

Whereas:

| (1) | Article 61a(1) of Regulation (EC) No 726/2004 requires that the Commission appoints representatives of healthcare professionals and patient organisations to the European Medicines Agency Pharmacovigilance Risk Assessment Committee. |
| --- | --- |

(1)

Article 61a(1) of Regulation (EC) No 726/2004 requires that the Commission appoints representatives of healthcare professionals and patient organisations to the European Medicines Agency Pharmacovigilance Risk Assessment Committee.

| (2) | In accordance with Article 61a(1) of Regulation (EC) No 726/2004, a public call for expression of interest has been undertaken by the Commission. The European Parliament has been consulted on the results of the evaluation of the applications received in the framework of this call for expression of interest. |
| --- | --- |

(2)

In accordance with Article 61a(1) of Regulation (EC) No 726/2004, a public call for expression of interest has been undertaken by the Commission. The European Parliament has been consulted on the results of the evaluation of the applications received in the framework of this call for expression of interest.

| (3) | The members and alternates of the Committee shall be appointed for a period of three years starting on 1 March 2013, which may be prolonged once, |
| --- | --- |

(3)

The members and alternates of the Committee shall be appointed for a period of three years starting on 1 March 2013, which may be prolonged once,

HAS ADOPTED THIS DECISION:

Sole Article

1.   The following are hereby appointed members and alternates of the Pharmacovigilance Risk Assessment Committee to represent healthcare professionals for a term of three years from 1 March 2013:

| — | Member: Filip Babylon, |
| --- | --- |

—

Member: Filip Babylon,

| — | Alternate: Kirsten Myhr. |
| --- | --- |

—

Alternate: Kirsten Myhr.

2.   The following are hereby appointed members and alternates of the Committee to represent patient organisations for a term of three years from 1 March 2013:

| — | Member: Albert van der Zeijden, |
| --- | --- |

—

Member: Albert van der Zeijden,

| — | Alternate: Marco Greco. |
| --- | --- |

—

Alternate: Marco Greco.

Done at Brussels, 28 February 2013.

For the Commission, On behalf of the President,

Tonio BORG

Member of the Commission

---

(1)  OJ L 136, 30.4.2004, p. 1.

1

---